elranatamab
pfizer
['mmsm', 'magnetismm-1', 'elranatamab', 'rafael ']
 presenting on elranatamab bcma bispecific magnetismm-1 sq as qw or qow. n=55 tcr 90% 30% hr genetics. crs 87% but down to 67% with step up and outlying g1/2. 80-1000 ug/kg. orr 64%, 38% cr. time to response 36 days
#ash2022rf #mmsm 
Chief Innovation Officer - Mayo Clinic in Arizona. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement